These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 20840324)
21. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Mohler JL; Chen Y; Hamil K; Hall SH; Cidlowski JA; Wilson EM; French FS; Sar M Clin Cancer Res; 1996 May; 2(5):889-95. PubMed ID: 9816246 [TBL] [Abstract][Full Text] [Related]
22. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Kramer G; Steiner GE; Handisurya A; Stix U; Haitel A; Knerer B; Gessl A; Lee C; Marberger M Prostate; 2002 Jun; 52(1):43-58. PubMed ID: 11992619 [TBL] [Abstract][Full Text] [Related]
23. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression. Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309 [TBL] [Abstract][Full Text] [Related]
24. Ultrastructural and biophysical studies on protein conformations of epithelium and stroma in benign prostatic hyperplasia before and after transurethral resection of the prostate. Hsu HS; Lin SY; Li MJ; Liang RC Ultrastruct Pathol; 2002; 26(3):137-41. PubMed ID: 12184371 [TBL] [Abstract][Full Text] [Related]
26. Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue. Wu ZL; Yuan Y; Geng H; Xia SJ Asian J Androl; 2012 Mar; 14(2):316-9. PubMed ID: 22157983 [TBL] [Abstract][Full Text] [Related]
27. Possible mechanisms of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: a neurohistochemical study. Zlotta AR; Raviv G; Peny MO; Noel JC; Haot J; Schulman CC J Urol; 1997 Mar; 157(3):894-9. PubMed ID: 9072594 [TBL] [Abstract][Full Text] [Related]
28. Phosphotyrosine antibodies preferentially react with basal epithelial cells in the dog prostate. Landry F; Chapdelaine A; Bégin LR; Chevalier S J Urol; 1996 Jan; 155(1):386-90. PubMed ID: 7490893 [TBL] [Abstract][Full Text] [Related]
29. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases. Brössner C; Petritsch K; Fink K; Auprich M; Madersbacher S; Adlercreutz H; Rehak P; Petritsch P Urology; 2004 Oct; 64(4):707-11. PubMed ID: 15491706 [TBL] [Abstract][Full Text] [Related]
32. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526 [TBL] [Abstract][Full Text] [Related]
33. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490 [TBL] [Abstract][Full Text] [Related]
34. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Kramer G; Mitteregger D; Marberger M Eur Urol; 2007 May; 51(5):1202-16. PubMed ID: 17182170 [TBL] [Abstract][Full Text] [Related]
35. Expression of androgen receptor and growth factors in premalignant lesions of the prostate. Harper ME; Glynne-Jones E; Goddard L; Mathews P; Nicholson RI J Pathol; 1998 Oct; 186(2):169-77. PubMed ID: 9924433 [TBL] [Abstract][Full Text] [Related]
36. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features. Aslan G; Irer B; Tuna B; Yorukoglu K; Saatcioglu F; Celebi I Pathol Res Pract; 2006; 202(2):93-8. PubMed ID: 16413692 [TBL] [Abstract][Full Text] [Related]